title: Polymorphisms of the interleukin-1 gene cluster and ovarian cancer.
abstract: OBJECTIVE
  Interleukin-1 (IL-1) is known to be critically involved in ovarian carcinogenesis. We investigated a panel of polymorphisms of the IL-1 and the IL-1 receptor antagonist (IL-1 RA) genes in patients with ovarian cancer.
  
  
  METHODS
  One hundred thirty-four patients with surgically staged ovarian cancer, 27 patients with borderline ovarian cancer, and 134 healthy controls were genotyped for three polymorphisms of the IL-1 gene (-889 C/T polymorphism of the IL-1alpha gene [IL1A], -511 C/T polymorphism of the IL-1beta promoter [IL1B promoter], a polymorphism of IL-1beta exon 5 [IL1B exon 5]), and an 86-base pair repeat in intron 2 of the IL-1 RA gene [IL1RN]) using polymerase chain reaction and pyrosequencing.
  
  
  RESULTS
  Allelic frequencies did not differ between patients with ovarian cancer and controls. In the ovarian cancer group, polymorphism did not correlate with any of the investigated clinicopathologic variables, including tumor stage, lymph node, and histologic grade. In univariate and multivariate models, there was no correlation between any polymorphism and patients' overall and disease-free survival.
  
  
  CONCLUSIONS
  We investigated interleukin polymorphisms in ovarian cancer but did not find any association between common polymorphisms of IL1A, IL1B, and IL1RN and the occurrence of ovarian cancer. Allelic variation within the IL-1 gene clusters does not seem to play a role in ovarian carcinogenesis and does not appear to be a useful tool for possible screening and risk evaluation.
authors.affiliation: Department of Obstetrics and Gynecology, University of Vienna Medical School, Vienna, Austria. lukas.hefler@akh-wien.ac.at
authors.forename: Lukas A
authors.initials: LA
authors.lastname: Hefler
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ludwig
authors.forename: Antje
authors.initials: A
authors.lastname: Lebrecht
authors.forename: Robert
authors.initials: R
authors.lastname: Zeillinger
authors.forename: Dan
authors.initials: D
authors.lastname: Tong-Cacsire
authors.forename: Heinz
authors.initials: H
authors.lastname: Koelbl
authors.forename: Sepp
authors.initials: S
authors.lastname: Leodolter
authors.forename: Clemens B
authors.initials: CB
authors.lastname: Tempfer
mesh_terms: D000483:Alleles; D018394:CA-125 Antigen / Q000032:analysis; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000235:genetics*; D007438:Introns; D008198:Lymph Nodes / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011379:Prognosis; D011401:Promoter Regions, Genetic; D012189:Retrospective Studies; D012795:Sialoglycoproteins / Q000235:genetics
chemical_list: D018394:CA-125 Antigen; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D012795:Sialoglycoproteins